Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies Inc. (BIAFW) pioneers noninvasive diagnostic solutions for early cancer detection, with a focus on improving patient outcomes through innovations like its CyPath Lung test. This page aggregates official company announcements, clinical milestones, and strategic developments for stakeholders tracking advancements in precision diagnostics.
Access timely updates on regulatory progress, partnership agreements, and research breakthroughs directly from the source. Our curated news feed includes earnings reports, product launch details, and peer-reviewed study results relevant to bioAffinity’s proprietary flow cytometry technologies.
Key coverage areas include diagnostic accuracy validations, licensing agreements with healthcare providers, and advancements in cellular analysis methodologies. Investors and researchers alike benefit from centralized access to verified information supporting data-driven decisions.
Bookmark this page for streamlined tracking of bioAffinity’s contributions to reducing invasive procedures in cancer care. Check regularly for authoritative updates on technologies reshaping modern diagnostics.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW) will present at the Cleveland Clinic’s Advances in Early Lung Cancer Detection symposium on
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) will ring the Nasdaq closing bell to celebrate its 2022 IPO. President and CEO Maria Zannes expressed gratitude for the opportunity, highlighting milestones leading to the launch of its noninvasive cancer detection product, CyPath® Lung. This test is aimed at early-stage lung cancer detection, enhancing treatment effectiveness and patient outcomes. The closing bell ceremony will be streamed live on various platforms, showcasing bioAffinity's commitment to innovation in early cancer diagnostics.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW) reported its financial results for 2022, marking a significant year after raising approximately $6 million from its IPO and converting nearly $16 million in debt to equity. The company generated $5,000 in revenue in 2022, up from zero in 2021, driven by its CyPath® Lung test. Key operational highlights include achieving 92% sensitivity and 87% specificity in detecting early lung cancer. Despite a net loss of $8.2 million in 2022, the company has raised additional funds through warrants. Management is optimistic about expanding the market for CyPath® Lung and plans a conference call on April 3, 2023, to discuss its results.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) announced the publication of a peer-reviewed paper in the Journal of Visualized Experiments (JoVE) detailing a protocol for preparing porphyrin-labeled compensation beads. These beads enhance the precision and cost-effectiveness of the company's CyPath® Lung test for early-stage lung cancer detection. The CyPath® Lung test demonstrated 92% sensitivity and 87% specificity in a recent clinical trial. bioAffinity holds an international patent pending for these proprietary beads, which are crucial for accurate fluorescence quantification in flow cytometry.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) will report its financial results for Q4 2022 on March 31, 2023, after market close. A conference call is scheduled for April 3, 2023, at 9:00 a.m. EDT to discuss these results. The company focuses on non-invasive cancer diagnostics and targeted treatments, highlighting its product CyPath® Lung, which is designed to detect early-stage lung cancer with high sensitivity and specificity. Future growth may depend on advancements in its therapeutic developments and the success of its revenue-generating products.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) has announced the appointment of Julie Anne Overton as the new Director of Communications. The company is leveraging the expertise of Havas Health & You and Trinity Life Sciences to enhance the brand identity and commercialization of its non-invasive lung cancer detection test, CyPath® Lung. This strategic partnership aims to create a patient-friendly diagnostic tool for physicians. CyPath® Lung has demonstrated a 92% sensitivity and 87% specificity in clinical trials, showcasing significant potential in the oncology sector.
bioAffinity Technologies has published results demonstrating that its non-invasive test, CyPath® Lung, can detect early-stage lung cancer with 92% sensitivity and 87% specificity in high-risk patients, significantly outperforming existing methods. The study published in Respiratory Research emphasized the importance of accurately predicting cancer in patients with small pulmonary nodules. The testing method relies on automated analysis and machine learning, allowing for rapid sample processing without the need for expert evaluation. This innovative approach is poised to enhance screening accuracy and is crucial for patient certainty.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) announced a Notice of Allowance from the USPTO for a patent on porphyrin compounds aimed at targeted cancer treatments. The patent, set to last until 2037, is held by its subsidiary OncoSelect. With over 1.9 million new cancer cases projected in the U.S. for 2022 and cancer care costs soaring to $150.8 billion in 2018, the company emphasizes the need for more precise treatments to enhance patient survival and quality of life. bioAffinity is also advancing its non-invasive lung cancer diagnostic system, CyPath® Lung, which boasts high sensitivity and specificity.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced key promotions and new hires aimed at enhancing its diagnostics division focused on early-stage lung cancer detection. Jennifer Rebeles, Ph.D., has been promoted to Vice President of Diagnostics, leading the development of CyPath® Lung, an advanced non-invasive test. Additionally, new research scientists Rossella Titone, Ph.D., and Alvaro Souto Padron de Figueiredo, Ph.D., have joined the team. The company emphasizes its commitment to innovation in lung disease diagnostics and cancer treatment.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) reports advancements in cancer treatment research. At the Cell Bio conference in Washington, D.C. from December 3-7, 2022, Dr. David Elzi will present his findings on silencing two genes, CD320 and LRP2, to target cancer cells while sparing normal cells. This research supports the development of their therapeutic platforms and aims to enhance understanding of gene silencing in cancer treatment. The company continues to advance its CyPath® Lung test for early-stage lung cancer diagnosis.
